MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease
- Last patient treated in MaaT Pharma’s Phase 3 ARES clinical trial
- Topline results publication now expected in January 2025
- Positive DSMB review of Phase 3 ARES trial announced in Q4 2023, with a favourable benefit/risk ratio and “high efficacy and low toxicity”
- Registration process to commence with submission expected in 2025 in Europe
Read the press release
